Literature DB >> 16490812

Monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm.

Harry V Gelboin1, Kristopher Krausz.   

Abstract

Monoclonal antibodies are reagents par excellence for analyzing the role of individual cytochrome P450 isoforms in multifunctional biological activities catalyzed by cytochrome P450 enzymes. The precision and utility of the monoclonal antibodies have heretofore been applied primarily to studies of human drug metabolism. The unique and precise specificity and high inhibitory activity toward individual cytochrome P450s make the monoclonal antibodies extraordinary tools for identifying and quantifying the role of each P450 isoform in the metabolism of a drug or nondrug xenobiotic. The monoclonal antibodies identify drugs metabolized by individual, several, or polymorphic P450s. A comprehensive collection of monoclonal antibodies has been isolated to human P450s: 1A1, 1A2, 2A6, 2B6, 2C8, 2C9, 2C family, 2C19, 2D6, 2E1, 3A4/5, and 2J2. The monoclonal antibodies can also be used for identifying drugs and/or metabolites useful as markers for in vivo phenotyping. Clinical identification of a patient's phenotype, coupled with precise knowledge of a drug's metabolism, should lead to a reduction of adverse drug reactions and improved drug therapeutics, thereby promoting advances in drug discovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490812     DOI: 10.1177/0091270005285200

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

Review 1.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

2.  Liver-specific cytochrome P450 CYP2C22 is a direct target of retinoic acid and a retinoic acid-metabolizing enzyme in rat liver.

Authors:  Linxi Qian; Reza Zolfaghari; A Catharine Ross
Journal:  J Lipid Res       Date:  2010-02-10       Impact factor: 5.922

3.  Expression of CYP4F2 in human liver and kidney: assessment using targeted peptide antibodies.

Authors:  Vandana Hirani; Anton Yarovoy; Anita Kozeska; Ronald P Magnusson; Jerome M Lasker
Journal:  Arch Biochem Biophys       Date:  2008-07-16       Impact factor: 4.013

4.  The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome P450 2D6.

Authors:  Natasha T Snider; Matthew J Sikora; Chitra Sridar; Thomas J Feuerstein; James M Rae; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2008-08-12       Impact factor: 4.030

5.  Blastocystis legumain is localized on the cell surface, and specific inhibition of its activity implicates a pro-survival role for the enzyme.

Authors:  Binhui Wu; Jing Yin; Catherine Texier; Michaël Roussel; Kevin Shyong-Wei Tan
Journal:  J Biol Chem       Date:  2009-11-13       Impact factor: 5.157

6.  The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.

Authors:  Gordon T Brown; Beatriz Gimenez Cash; Daniela Blihoghe; Petronella Johansson; Ayham Alnabulsi; Graeme I Murray
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

7.  The prognostic value of CYP2C subfamily genes in hepatocellular carcinoma.

Authors:  Xiangkun Wang; Tingdong Yu; Xiwen Liao; Chengkun Yang; Chuangye Han; Guangzhi Zhu; Ketuan Huang; Long Yu; Wei Qin; Hao Su; Xiaoguang Liu; Tao Peng
Journal:  Cancer Med       Date:  2018-02-26       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.